Meta AnalysisID 7693
评估新型冠状病毒肺炎门诊抗凝治疗的有效性和安全性：临床结局的Meta分析
CRD42023460697
Is anticoagulation for patients with COVID-19 beneficial in an outpatient setting?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7693
- Evidence Id
- 16251
- Core Evidence Id
- 16251
- Source Meta Analysis Id
- 7687
- Herb2 Meta Analysis Id
- HBMA007687
- Crd Id
- CRD42023460697
- Title
- Assessing the efficacy and safety of outpatient anticoagulation in COVID-19: a meta-analysis of clinical outcomes
- Review Question
- Is anticoagulation for patients with COVID-19 beneficial in an outpatient setting?
- Study Type Included
- Randomized controlled trials will be used. Observational studies will not be included.
- Condition Being Studied
- COVID-19, responsible for over millions of fatalities to date, has triggered a worldwide health emergency. This pandemic is characterized by localized inflammatory alterations in the lungs, alongside a heightened proclivity for blood clot formation, immune system irregularities, damage to the endothelial lining, and multiple organ failures. Anticoagulation for hospitalized patient with COVID-19 has been and is still being researched. However, the question remains whether to anticoagulate patients who tested positive for COVID-19 but not sick enough to be hospitalized. Does anticoagulation have any mortality benefit? Does it decrease the risk of thromboembolic events? Does it prevent hospitalization? Is there a bleeding risk accompanies those type of patients when anticoagulated? Is the risk of adverse events worth it to anticoagulate those patients? These are all questions that the team will try to answer by pursuing the data of clinical trials targeting this type of population.
- Participant
- Patients who tested positive for COVID-19 and do not require hospitalization i.e COVID-19 patients in the outpatient setting.
- Animal
- Human Disease Modelled
- Intervention
- Anticoagulation including heparin, low-molecular weight heparin, DOACS including Apixaban, Rivaroxaban etc
- Comparator Control
- Placebo will be used as control.
- Main Outcome
- Mortality
- Outcome Measure
- Additional Outcome
- Thromboembolic events, cardiovascular events and disease worsening/progression
- Study Method
- Intervention, Meta-analysis, Systematic review
- Keyword
- Anticoagulants; Blood Coagulation; COVID-19; Humans; Outpatients
- Contact
- Omer Ahmed [email protected]
- Organisational Affiliation
- Rochester Regional Health, Unity Hospital
- Funding Source
- No funding
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- United States of America
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-09-05
- Registration Date
- 2023-09-11
- Anticipated Start Date
- 2023-09-05
- Anticipated Completion Date
- 2023-10-31
- Title Cn
- 评估新型冠状病毒肺炎门诊抗凝治疗的有效性和安全性：临床结局的Meta分析
- Title En
- Assessing the efficacy and safety of outpatient anticoagulation in COVID-19: a meta-analysis of clinical outcomes
- Bilingual Status
- complete